Chronic treatment with BRL 35135 potentiates the action of insulin on lipid metabolism

Eur J Pharmacol. 1997 Aug 6;332(2):215-8. doi: 10.1016/s0014-2999(97)01104-7.

Abstract

The effects of a beta 3-adrenoceptor agonist on insulin-induced changes in lipid metabolism were studied in obese male Zucker (fa/fa) rats during euglycaemic clamp. Rats were treated with BRL 35135 (R*, R*-(+/-)-methyl-4-[2-[2-hydroxy-2-(3-chlorophenyl)-ethyl-amino]-propyl] phenoxyacetate hydrobromide) (0.5 mg/kg per day in drinking water) for three weeks before an euglycaemic hyperinsulinaemic clamp was performed. Insulin infusion lowered serum non-esterified fatty acids and plasma glycerol more efficiently in BRL 35135-treated than in control rats although plasma insulin remained significantly lower in the BRL 35135-treated than in the control rats during the clamp. In conclusion, chronic treatment with BRL 35135 potentiates the effect of insulin on lipid metabolism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Agonists / pharmacology*
  • Animals
  • Drug Synergism
  • Hyperinsulinism / blood
  • Insulin / pharmacology*
  • Insulin Resistance
  • Lipids / blood*
  • Male
  • Obesity / metabolism
  • Phenethylamines / pharmacology*
  • Rats
  • Rats, Zucker

Substances

  • Adrenergic beta-Agonists
  • Insulin
  • Lipids
  • Phenethylamines
  • BRL 35135